Synthesis, structure and antibacterial evaluation of Some N-substituted 3-amino-5-hydroxy-4-phenyl-1H-pyrazole-1-carboxamides

Medicinal Chemistry

Volumn 7, Issue 6, 2011, Pages 697-703

  Pitucha, Monika ^a   Kosikowska, Urszula ^a   Mazur, Liliana ^b   Malm, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Antibacterial activity; Pyrazole; Synthesis; X ray analysis

Indexed keywords

AMPICILLIN; CEFUROXIME; N (1 NAPHTHYL) 3 AMINO 5 HYDROXY 4 PHENYL 1H PYRAZOLE 1 CARBOXAMIDE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 80655144324     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611797928433     Document Type: Article

References (32)

1. Elguero, J.; Goya, P.; Jagerovic, N.; Silva, A. M. S. Pyrazoles as Drugs: Facts and Fantasies. In Targets in Heterocyclic Systems; Attanasi, O.A.; Spinelli, D., Eds.; Royal Society of Chemistry: Cambridge, 2002; Vol. 6, pp. 52-98.
2. Lamberth, C. Chemistry in Crop Protection. Part 4. Pyrazole Chemistry in Crop Protection. Heterocycles, 2007, 71, 1467-1502.
3. Lee, K.Y.; Kim, J.M.; Kim, J.N. Regioselective synthesis of 1,3,4,5-tetrasubstituted pyrazoles from Baylis-Hillman adducts. Tetrahedron Lett., 2003, 44, 6737-6740. (Pubitemid 36966037)
4. Soliman, R.; Darwish, S.A. Antidiabetic activity of some 1-substituted 3,5-dimethylpyrazoles. J. Med. Chem., 1983, 26, 1659-1663. (Pubitemid 14245365)
5. Jia, Z.J.; Wu, Y.; Huang, W.; Zhang, P.; Song, Y.; Woolfrey, J.; Sinha, U.; Arfsten, A.E.; Edwards, S.T.; Hutchaleelaha, A.; Hollenbach, S.J.; Lambing, J.L.; Scarborough, R.M.; Zhu, B. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 1229-1234. (Pubitemid 38229862)
6. Liu, X.L.; Cup, P.; Song, B.A.; Bhadury, P.S.; Zhu, H.L.; Wang, S.F. Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3- substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives. Bioorg. Med. Chem., 2008, 16, 4075-4082. (Pubitemid 351484019)
7. Dogne, J.M.; Hanson, J.; Supuran, C.T.; Pratico, D. Coxibs and cardiovascular side-effects: From light to shadow. Curr. Pharm. Design., 2006, 12, 971-975.
8. O'Connor, J.P.; Lysz, T. Celecoxib, NSAIDs, and the skeleton. Drugs Today, 2008, 44, 693-709.
9. Lange, J.H. M.; Kruse, C.G. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chemical Record, 2008, 8, 156-168.
10. Jacobsen, D.; McMartin, K. 4-Methylpyrazole: Present status. J. Toxicol. Clin. Toxicol., 1996, 34, 379-381.
11. De Brabander, N.; Wojciechowski, M.; De Decker, K.; De Weerdt, A.; Jorens P.G. Fomepizole as a therapeutic strategy in pediatric methanol poisoning. A case report and review of the literature. Euro. J. Pediatrics, 2005, 164, 158-161. (Pubitemid 40558179)
12. Genin, M.J.; Biles, C.; Keiser, B.J.; Poppe, S.M.; Swaney, S.M.; Tarpley, W.G.; Yagi, Y.; Romero, D.L. Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: Lead identification and SAR of 3-and 4-substituted derivatives. J. Med. Chem., 2000, 43, 1034-1040. (Pubitemid 30152308)
13. Wei, F.; Zhao, B.W.; Huang, B.; Zhang, L.; Sun, C.H., Dong, W.L.; Shin, D.S.; Miao, J.Y. Design, synthesis, and preliminary biological evaluation of novel ethyl 1-(2'-hydroxy-3'-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxylate. Bioorg. Med. Chem. Lett., 2006, 16, 6342-6347. (Pubitemid 44712059)
14. Boehm, H.J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem., 2000, 43, 2664-2674. (Pubitemid 30463915)
15. Gagnon, P.E.; Boivin, J.L.; Jones, R.N. Synthetic and spectrometric studies of some pyrazolones. Canadian Journal of Research, 1949, 27B, 190-204.
16. Oxford Diffraction, Xcalibur CCD System, CrysAlis Software System, Version 1.171. Oxford Diffraction Ltd., 2009.
17. Sheldrick, G.M. A short history of SHELX. Acta Cryst., 2008, A64, 112-122.
18. Pitucha, M.; Polak, B.; Świeboda, R.; Kosikowska, U.; Malm, A. Determination of the lipophilicity of some new derivatives of semicarbazide and 1,2,4-triazol-5-one with potential antibacterial activity. Z. Naturforsch., 2009, 64b, 570-576.
19. CLSI. Performance standards for antimicrobial susceptibility testing; Eighteenth International Supplement. CLSI document M7-MIC, Wayne, PA, Clinical Laboratory Standards Institute, 2008.
20. Gagnon, P.E; Boivin, J.L. Synthesis of amino acids from substituted cyanoacetic esters. Can. J. Res., 1948, 26, 503-510.
21. Drobniewski, F.A. Bacillus cereus and related species. Clin. Microbiol. Rev., 1993, 6, 324-338. (Pubitemid 23306590)
22. Zingg, W.; Demartines, N.; Imhof, A.; Senn, G.; Ruef, C. Rapid colonization with methicillin-resistant coagulase-negative staphylococci after surgery. World J. Surg., 2009, 33, 2058-2062.
23. Khalil, H.; Williams, R.J.; Stenbeck, G.; Henderson, B.; Meghji, S.; Nair, S.P. Invasion of bone cells by Staphylococcus epidermidis. Microbes Infect., 2007, 9, 460-465. (Pubitemid 46436543)
24. Kluytmans, J.; van Belkum, A.; Verbrugh, H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev., 1997, 10, 505-520. (Pubitemid 27359263)
25. Vuong, C.; Otto, M. Staphylococcus epidermidis infections. Microbes Infect., 2002, 4, 481-489. (Pubitemid 34270685)
26. Cohen, J.; Pinching, A.J.; Rees, A.J.; Peters, D.K. Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q. J. Med., 1982, 51, 1-15. (Pubitemid 13160887)
27. Von Graevenitz, A. The role of opportunistic bacteria in human disease. Ann. Rev. Microbiol., 1977, 31, 447-471.
28. Reddy, S.; Wanchu, A.; Gupta, V.; Bambery, P. Profile of opportunistic infections among patients on immunosuppressive medication. APLAR J. Rheumatol., 2006, 9, 269-274. (Pubitemid 44473298)
29. Ronald, A. The etiology of urinary tract infection: Traditional and emerging pathogens. Dis. Mon., 2003, 49, 71-82. (Pubitemid 36350776)
30. Rosenberg, A.L.; Seneff, M.G.; Atiyeh, L.; Wagner, R.; Bojanowski, L.; Zimmerman, J.E. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: Implications for future care in the age of increasing antiretroviral resistance. Crit. Care Med., 2001, 29, 548-556. (Pubitemid 32225296)
31. Schmidt-Ioanas, M.; de Roux, A.;. Lode, H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr. Opin. Crit. Care., 2005, 11, 481-486. (Pubitemid 41482705)
32. Li, Z.; Francisco, G.D.; Hu, W.; Labthavikul. P; Petersen, P.J.; Severin, A.; Singh, G.; Yang, Y.; Rasmussen, B.A.; Lin, Y.-I.; Skotnicki, J.S.; Mansour, T.S. 2-Phenyl-5,6-dihydro-2Hthieno[ 3,2-c]pyrazol-3-ol derivatives as new inhibitor of bacterial cell wall biosynthesis. Bioorg. Med. Chem. Lett., 2003, 13, 2591-2594. (Pubitemid 36830780)